NCT04417504

Brief Summary

The mobilizing programme MobFood - mobilizing scientific knoweledge and technology to answer the current nutrition market challenges - is formed by a consortium of 47 collaborative entities, between the industry and ENESIIs (Entidades Não Empresariais do Sistema de Investigação e Inovação) and is financed by Structural European Funds of Investment. The project is currently investigating and undertaking collaborative scientific and technological strategies based on R\&D and innovation, in order to boost and promote a more competitive national food industry, capable of overcoming the current challenges, including those of the Millennial Generation. This group is particularly conscious of the impact of food behaviour and food choices on health but extremely vulnerable to dietary imbalance. Strategies to improve Millenials' nutrition while providing conscious food products are needed. This study is a randomised, cross-over controlled trial designed to test the metabolic effect, particularly in terms of appetite control and glycaemic response of a breakfast kit (nutritionally balanced and innovative), recently developed as part of the collaborative project MobFood\_PPS4.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 1, 2020

Completed
Same day until next milestone

Study Start

First participant enrolled

June 1, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 4, 2020

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2020

Completed
Last Updated

June 9, 2020

Status Verified

November 1, 2019

Enrollment Period

4 months

First QC Date

June 1, 2020

Last Update Submit

June 4, 2020

Conditions

Outcome Measures

Primary Outcomes (6)

  • Differences in the incremental area under the curve (iAUC, mg/dl*min) for glucose response between the 2 arms

    The iAUC for glucose will be calculated based on the concentration curve following consumption of the test and control products, over 2h

    at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1)

  • Differences in the iAUC (pmol/l*min) for glucagon-like peptide-1 (GLP-1) between the 2 arms

    The iAUC for GLP-1 will be calculated based on the concentration curve following consumption of the test and control products, over 3h

    at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1)

  • Differences in the iAUC (pmol/l*min) for peptide YY (PYY) between the 2 arms

    The iAUC for PYY will be calculated based on the concentration curve following consumption of the test and control products, over 3h

    at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1)

  • Differences in the iAUC (pmol/l*min) for cholecystokinin (CKK) between the 2 arms

    The iAUC for CKK will be calculated based on the concentration curve following consumption of the test and control products, over 3h

    at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1)

  • Differences in the iAUC (pmol/l*min) for ghrelin between the 2 arms

    The iAUC for ghrelin will be calculated based on the concentration curve following consumption of test and control products, over 3h

    at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1)

  • Differences in the iAUC (pmol/l*min) for glucagon between the 2 arms

    The iAUC for glucagon will be calculated based on the concentration curve following consumption of the test and control products, over 3h

    at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1)

Secondary Outcomes (3)

  • Differences in the iAUC (mg/dl*min) for triacylglycerides (TG) between 2 arms

    at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1)

  • Differences in the iAUC for (mmol/l*min) non-esterified fatty acids (NEFA) between 2 arms

    at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1)

  • Differences in subjective feelings of hunger/satiety between the 2 arms

    at CID1 (1 week after screening) and CID2 (at least 2 days after visit 1)

Study Arms (2)

MobFood breakfast kit

EXPERIMENTAL
Other: MobFood breakfast kit

Control isocaloric breakfast

EXPERIMENTAL
Other: Control isocaloric breakfast

Interventions

Cereal biscuit with orange fruit, cheese with fruit preparation and beverage based on oat, milk and mocha (without added sugar), specifically developed for the project MobFood\_PPS4.

MobFood breakfast kit

White bread, butter and milk.

Control isocaloric breakfast

Eligibility Criteria

Age23 Years - 38 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Male or female;
  • Born between 1981 and 1996;
  • Body mass index (BMI) between 18.5 kg/m2 and 24.9 kg/m2;
  • Normoglycemic according to American Diabetes Association criteria \[Fasting Plasma Glucose \< 100 mg/dl, 2-h plasma glucose value during a 75 g oral glucose tolerance test (OGTT) \< 140 mg/dl)\];
  • Healthy.

You may not qualify if:

  • Overweight or obese (BMI ≥ 25,0 kg/m2);
  • Recent body weight loss/gain \>10%, within previous 3 months;
  • Being on a weight loss/other special diet (e.g. Paleo diet, Atkins diet, flexitarian diet or ketogenic diet), within previous 3 months;
  • Clinically significant illness, including:
  • type 1 or type 2 diabetes; liver disease e.g. cirrhosis; malignancy; pancreatitis or other malabsorption; gastrointestinal disorders e. g. intestinal bowel disorder, celiac disease; previous weight loss surgery e.g. bariatric surgery; chronic respiratory, neurological, psychiatric, musculoskeletal diseases/conditions; diagnosed eating disorders.
  • Individuals who don't regularly consume breakfast;
  • Having taken antibiotics within the 12 weeks prior to beginning the study;
  • Taking other medication that could potentially affect body weight, glucose metabolism and/or appetite (e.g. GLP-1 analogues);
  • Being engaged in competitive sports;
  • Having \>14 or \>8 (males and females, respectively) alcoholic units/week; misuse of drugs;
  • Having donated blood within one month prior to the beginning of the study;
  • Nut or milk allergy, or other food allergy or intolerance that would compromise compliance with the study protocol;
  • Pregnant or breastfeeding.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NOVA Medical School, NOVA University of Lisbon

Lisbon, Portugal

Location

MeSH Terms

Conditions

Feeding Behavior

Condition Hierarchy (Ancestors)

Behavior, AnimalBehavior

Central Study Contacts

Conceição Calhau, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 1, 2020

First Posted

June 4, 2020

Study Start

June 1, 2020

Primary Completion

September 30, 2020

Study Completion

October 31, 2020

Last Updated

June 9, 2020

Record last verified: 2019-11

Locations